Frontiers in Oncology (Oct 2020)

Case Report: A Chronological Combination Treatment of Icotinib, Osimertinib, and Crizotinib on Lung Adenocarcinoma Guided by Serial Genetic Tests of Circulating Tumor DNA and Sediment Cell Genomic DNA From Pleural Effusion

  • Zhihua Miao,
  • Tianhao Mu,
  • Longying Liu,
  • Jingjie Rao,
  • Min Jin,
  • Zhizheng Wang,
  • Hui Wang,
  • Chao Lu,
  • Xiaolin Gong,
  • Dongcai Zheng,
  • Daoming Zheng,
  • Xin Li,
  • Yingmei Li,
  • Shifu Chen,
  • Xinhua Shu

DOI
https://doi.org/10.3389/fonc.2020.561341
Journal volume & issue
Vol. 10

Abstract

Read online

Precision medicine has been getting more attention in lung cancer treatment. Here, we report an unusual case of a 71-year-old Chinese male patient with poorly differentiated lung adenocarcinoma with lymph node metastasis. A 5 years' treatment history of this patient is reported. By serial genetic tests of circulating tumor DNA (ctDNA) from peripheral blood and sediment cell genomic DNA (PE-sDNA) from pleural effusion, a novel chronological combination treatment of icotinib, osimertinib, and crizotinib was adopted for the present genetic mutations, including EGFR exon 19 deletion, EGFR p.T790M, and MET amplification.

Keywords